Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus
a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care
outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have
previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be
determined for longitudinal outcomes of opioid abstinence, compliance with outpatient
buprenorphine maintenance, quality of life, and mood.